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ABSTRACT
The defining feature of cancer cachexia is extensive weight loss and skeletal muscle atrophy. It is clinically
important because cachexia reduces patient survival, results in functional impairment, and is estimated to
be directly responsible for 20-40% of cancer deaths. Unfortunately, no clinical therapy exists and therefore,
it is important to understand the molecular mechanisms responsible for rapid muscle wasting. Compared
to limb muscles, the diaphragm is relatively understudied in cancer cachexia, but is likely to be adversely
affected because cachexia is a systemic disease. Wasting of the primary inspiratory muscle may result in
difficulty breathing and inability to adjust minute ventilation in response to a respiratory challenge. Based
on emerging evidence, it is clear that oxidative stress is present in cachexia-induced wasting of the
diaphragm; we developed the hypothesis that mitochondrial dysfunction in the diaphragm precedes
cachexia. METHODS: 1X106 Lewis Lung Carcinoma cells (LLC) or Phosphate-Buffered Saline (PBS,
control) were implanted to the hind-flank of C57BL6/J mice at 8 wks of age. Tumors were allowed to
develop for 1, 2, 3, or 4 wks. At designated time points diaphragms were collected and mitochondrial
function was assessed by respiration and ROS production. RESULTS: Cancer cachexia was evident only at
the 4 wk time point demonstrated by decrease in body mass and muscle atrophy in several limb muscles.
Mitochondrial respiration, assessed by respiratory control ratio (state3/state 4 respiration), was
significantly lower at 1 wk (p<0.05) post-implantation and stayed depressed. ROS production was
significantly elevated early in the time course (2 wk time point) compared to control (p<0.05), however
wks 3 and 4 were not different from control. CONCLUSIONS: The molecular events that lead to muscle
atrophy in cancer cachexia are unknown. We demonstrate that two hallmarks of mitochondrial
dysfunction, altered respiration and ROS production, occur in the diaphragm well before the cancer
cachexia phenotype is evident in the LLC model. These data suggest that the mitochondria are likely a
suitable target to treat or prevent cancer cachexia-induced muscle wasting in the diaphragm.
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